Cancer Stem Cells and Molecular Biology Test in Colorectal Cancer: Therapeutic Implications

Rustam Effendi-YS


Colorectal cancer (CRC) is the third most frequent cancer in males, the second in females, and is the second leading cause of cancer related death worldwide. Within Indonesia’s 250 million population, the incidence rates for CRC per 100,000 population were 15.2 for males and 10.2 for females, and estimated 63,500 cases per year.  More than 50% of colorectal cancer patients will develop metastasis. CRC is still the main cause of tumor-related death, and although most CRC patients are treated with surgery to remove the tumor tissue, some of the CRC patients recurred. Chemotherapy used as adjuvant or neoadjuvant therapy also has several problems, in which these treatments are useless in tumor cells with chemo-resistance. Molecular testing of CRC from tumor tissues has important implications for the selection of treatment. Biomarkers can be used as prognostic value, molecular predictive factors, and targeted therapy. Recent research reported that, cancer stem cells (CSCs) are considered as the origin of tumorigenesis, development, metastasis and recurrence. At present, it has been shown that CSCs existed in many tumors including CRC. This review aims to summarize the issue on CSCs, and the future development of drugs that target colorectal cancer stem cells.


Colorectal cancer; cancer stem cells; biomarkers; chemoresistance; target therapy


Torre LA, Bray F, Siegel RL, Ferlay J, Tieulent JL, Jemal A. Global cancer statistics. Ca Cancer J Clin 2015;65:87-108.

GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012 Icited:March 9,2016). Available from url:,aspx

Effendi-YSR. Economic burden of colorectal cancer: Prevention vs Treatment. In: Simadibrata M, Makmun D, Abdullah M, Syam AF, eds. Proceeding Book. Indonesian Digestive Disease Week, Jakarta 2016. p 50-8.

Ramasamy TS, Ayob AZ, Myint HHL, Thiagarajah S and Amini F. Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy. Cancer cell Int.2015;15:96

Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.

Markowitz SD, Bertagnolli MM. Molecular orgins of cancer: Moecular basis of colorectal cancer. N Engl J Med.2009;361:2449-60.

Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC,Dirks PB. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-23.

Collusi D, Brandi G, Bazzoli F, and Ricciardiello. Molecular pathways involved in colorectal cancer: Impications for disease behaviour and prevention. Int J Mol Sci. 2013;14:1635-85.

Zoratto F, Rossi L, Verrico M, Papa A, Basso E, Zullo A, at al. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: Implications for molecular diagnosis. Tumour Biol 2014;35:6195-206

Farkas SA, Vymetalkova V, Vodickova L, Vodicka V, Nilsson TK. DNA methylation changes in genes frequently mutated in sporadic colorectal cancer and in the DNA repair and Wnt/β-catenin signaling pathway genes. Epigenomics 2014;6:179-91.

Effendi YSR, Zain LH, Siregar GA, Lubis HR,Damanik HA, Laksmi Li, et al. Adeno atous polyposis coli, mismatch repair, and microsatellite instability i colorectal cancer based on locations. PubMed. Acta Med Indones.2013;45(4):275-83.

Effendi YSR, Rey I. Molecular diagnostics in colorectal cancer. Indones J Gastronterol Hepatol Dig Endosc 2015;16(1): 26-33.

Seal BS, Sullivan SD, Ramsey SD, Shermock KM, Ren J, Kreilick C, et al. Systemic herapy for colorectal cancer: Patterns of chemotherapy and biologic therapy use in in nationally representative US claims database. BioDrugs 2014;28:229-36.

Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-87.

Chen X, Liu Y, Yang HW, Zhou S, Cheng C, Zheng MW, et al. SKLB-287.a? novel oral multikinase inhibitor of EGFR and VEGFR2, exhibits potent antintumor activity in LoVo colorectal tumor model. Neoplasma.2014;61:514-22.

Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, et al. Anti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases. World J Gastroenterol 2014;20: 4263-75.

Jie Li C, Zhang X, Wei Fan-G. Updates in colorectal cancer stem research. J Can Res Ther 2014;10:233-9.

Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cells concept. J Clin Invest 2010;120:41-50.

Stone JG, Robertson D, Houlston RS. Immunohistochemistry for MSH2 and MLH1: a method for identifying mismatch repair deficient colorectal cancer. J Clin Pathol 2001;54:484-7.

Legolvan MP, Taliano RJ, and Resnick MB. Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach. Hum Pathol 2012;43:1157-68.

Huth L, Jakel J, and Dahl E. Molecular diagnostic applications in colorectal cancer. Microarrays 2015;3:168-79.

Sohal D, Sepulveda AR, and Sun W. Targeted therapies and molecular diagnostics of Gastrointestinal cancer. In: Sepulveda AR, Lynch JP, eds. Molecular Pathology of Neoplastic Gastrointestinal Diseases. Molecular Pathology Library. Springer Sci +Business Media New York.2013.pp.33-41.

Vilar E, Gruber SB: Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010;7:153-62.

Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitame J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol 2012.;27:1423-31.

Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet 2012;81:303-11.

Tsang AH, Cheng KH, Wong ASP, Ng SS, Ma BB, Chan CM, et al. Current and future molecular diagnostics in colorectal cancer and colorectal adenoma. World J Gastroenterol. 2014;20:3847-57.

Hrasovec S, and Glavac D. MicroRNA as novel biomarkers in colorectal cancer. Front Genet 2012;3:1-9.

Wang Ke, Wu X, Wang J, Huang J. Cancer stem cell theory: therapeutic implications for nanomedicine. Int J Nanomedicine.2013;8:899-908.

Gangemi R, Paleari L, Orengo AM, Cesareo A, Chessa L, Ferrini S, et al. Cancer stem cells: a new paradigm for undersanding tumor growth and progression and drug resistance. Curr Med Chem.2009;16(14):1688-1703.

McCubrey JA, Abrams SL, Stadelman K, Chappell WH, La Hair M, Franklin RF, et al. Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Adv Enzyme Regul.2010;50(1): 285-307.

Rich JN, Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell.2007;1(4): 353-5

Song L, Li Y. The role of stem cell DNA methylation in colorectal carcinogenesis. Stem Cell Rev and Rep DOI 10.1007/s12015-016-9672-6. Springer. Published online: 11 July 2016.

Roostaee A, Benoit YD, Boudjadi S, and Beaulieu JF. Epigenetics in intestinal epithelial cell renewal. J Cell Physiol. 2016; 9999:1-7.

Jones PA, and Baylin SB. The epigenomics of cancer. Cell.2007; 128: 683-92.

Baylin SB, Ohm JE. Epigenetic gene silencing in cancer- a mechanism for early oncogenic pathway addition?. Nature Rev Cancer.2006; 6: 107-16.

Song L, Li Y, He B, and Gong Y. Development of small molecules targeting the Wnt signaling pathway in cancer stem cdells for the treatment of colorectal cancer. Clin Colorectal Cancer. 2015;14: 133-45.

Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 2010;23:450-7.

Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009;28:4065-74.

Saigusa S, Tanaka K, Toiyama Y, Yakoe T, Okugawa Y, Koike Y, et al. Clinical significance of CD133 and hypoxia inducible factor-1a gene expression in rectal cancer after preoperative chemoradiotherapy. Clin Oncol (R Coll Radiol) 2011;23:323-32.

Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Kawamoto A, et al. Immunochemical features of CD133 expression: Association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep.2010;24:345-50.

Zeuner A, Todaro M, Stassi G, and De Maria R. Colorectal cancer stem cells: From the crypt ti the clinic. Cell Stem Cell 2014; 15: 692-705.

Ahmad A, Habeeb Z, Al-Mousa M, Al-Shawaf G, Al-Awadi M, Algooneh A. Cancer stem cells, therapeutic implications. Kuwait Med J. 2015;47(2):97-114.

Han L, Shi S, Gong T, Zhang Z, Sun X. Cancer stem cells: therapeutic implications and perspectives in cancer therapy. Acta Phar Sinica B 2013;3(2): 65-75.

Wu WK, Wang XJ, Cheng AS, Luo MX, Ng SS, To KF, et al. Dysregulation and crosstalk of cellular signaling pathway in colon carcinogenesis. Crit Rev Oncol Hematol 2013;86:251-77.

Zhang K, Civan J, Mukherjee S, Patel F, Yang H. Genetic variations in colorectal cancer risk and clinical outcome. World J Gastroenterol 2014;20:4167-77.

Hsu HC, Liu YS, Tseng KC, Tan BC, Chen SJ, Chem HC. LGR5 regulates survival trough mitochondria-mediated apoptosis and by targetting the Wnt/β-catenin signaling pathway in colorectal cancer cells. Cell Signal 2014;26:2333-42.

He S, Zhou H, Zhu X, Hu S, Fei M, Wan D, et al. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance. Biomed Pharmacother 2014;68:507-13.

Todaro M, Gaggianesi M, Catalano V, Benfante A, Lovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem cell 2014;14:342-56.

Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML, et al. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 2010;70:1469-78.

Van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenoma into goblet cells. Nature 2005;345:959-63.

Whissell G, Montagni E, Martinelli P, Hernando-Momblona X, Sevillano M, Jung P, et al. The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression. Nat Cell Biol 2014;16:695-707.

Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, et al. Bone morphogeneic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 2011;140:297-309.

Ricci-Vittiani L, Mollinari C, di Martino S, Biffoni M, Pillozzi E, Pagliuca A, et al. Thymosin beta 4 targeting impairs tumotigenic activity of colon cancer sem cells. FASEB J 2010; 24:4291-301.

Full Text: PDF


  • There are currently no refbacks.